Skip to Content
Healthcare Professionals

Treatment-specific guidance

On this page you will find links to BAD guidance relating to specific drugs or treatments, during COVID-19.


Covid-19: Updated Guidance For Managing Patients On Isotretinoin During the Coronavirus Pandemic (September 2020)

Covid-19: Guidance For Managing Urticaria Patients on Omalizumab During the Coronavirus Pandemic

Dermatology Grid: Advice Regarding Self-Isolation and Immunosuppressed Patients: Adults, Paediatrics and Young People

Covid-19: Clinical Guidance for the Management of Skin Cancer Patients during the Coronavirus Pandemic 

Royal College of Radiologists: Non-melanoma Skin Cancer and Covid-19

Dermatology Covid-19 Registry

The AAD has created a dermatology COVID-19 registry to understand dermatologic manifestations of the COVID-19 virus.

The survey is for all healthcare professionals taking care of COVID-19 patients who develop dermatologic manifestations, or dermatology patients with an existing condition who then develop COVID-19. 


Special Interest Groups Guidance:

The British Society for Dermatological Surgery has released a statement on the reintroduction of cancer services post-COVID:

British Phototherapy Group on Phototherapy, PDT and Photodiagnostics (updated 06/04/2021):
- Phototherapy:
- Photodynamic Therapy (PDT):
- Photodiagnostics:

British Society for Cutaneous Allergy statement on the reintroduction of patch testing services, which has been recently updated (31/03/2021):
Sample questionnaire for patch test pre-planning

British Society for the Study of Vulval Disease on restarting vulval services:

British Society of Paediatric Dermatology on restarting paediatric services (updated 30/04/2021) 

In summary, all patients should be triaged for COVID-19 before starting treatment, with those testing positive unable to attend consultations or appointments. Where limited resources remain, patients presenting with severe symptoms should be prioritised. There should be adequate spacing between appointments, with ideally enough time to clean where necessary.  It is also important to reduce wait times for patients, to reduce the risk of COVID transmission.

2ww Pathway Changes

The National Cancer team have been working closely with the Dermatology team of the NOTP and the BAD on innovations to the 2-week wait pathway. These remove the need for all patients to be seen face-to-face in a specialist hospital setting.  

There are two pathways to add to the face-to-face pathway: 

  • a virtual/remote pathway using high-quality images, including dermoscopic images  

  • community-based rapid access single lesion ‘Spot Clinics’.  

The document can be found here, and it is also available on the NHS Future Forums (sign in required):


Back to top